NVO news, real time NVO stock news, Novo-Nordisk A/S news today

News

NVO

49.27

+0.68%

0.34

Hims & Hers short interest climbs amid legal risk related to weight loss pill

Seeking Alpha · 2h ago

RFK Jr. HHS shakeup continues as deputy secretary leaving post - report

Seeking Alpha · 4h ago

Novo Nordisk Advances Oral Semaglutide Into Youth Diabetes Care: What Investors Should Know

TipRanks · 4h ago

Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential

Seeking Alpha · 7h ago

Biocon aims for revenue surge with rollout of generic weight-loss drugs

Reuters · 8h ago

Novo's Wegovy pill tracks over 38,000 prescriptions in fifth week

Reuters · 8h ago

Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)

TipRanks · 9h ago

Eli Lilly boosts weight loss pill inventory ahead of FDA decision

Seeking Alpha · 9h ago

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026

The Motley Fool · 9h ago

FDA Crackdown Reshapes Wegovy Competition And Risks For Novo Nordisk Investors

Simply Wall St · 9h ago

ANALYSIS-US could take action including fines against Hims after brief Wegovy copy launch

Reuters · 10h ago

Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms

Benzinga · 10h ago

Novo Nordisk price target lowered to DKK 360 from DKK 415 at Berenberg

TipRanks · 1d ago

BUZZ-Hims & Hers falls, set for tenth straight day of losses

Reuters · 1d ago

Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market

Benzinga · 1d ago

Novo Nordisk Expands GLP-1 Ambitions With Completed Liver and Alcohol Use Trial

TipRanks · 1d ago

Novo said to eye Ireland to produce Wegovy pill for international markets

Seeking Alpha · 1d ago

Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)

TipRanks · 1d ago

Analysts Offer Insights on Healthcare Companies: Avantor (AVTR), Novo Nordisk (NVO) and Neurocrine (NBIX)

TipRanks · 1d ago

West Pharma forecasts 2026 profit above estimates on strong demand for drug components

Reuters · 1d ago

Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.

About NVO

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.